Zakrzewska, JM;
Wu, N;
Lee, JYK;
Werneburg, B;
Hoffman, D;
Liu, Y;
(2018)
Characterizing Treatment Utilization Patterns for Trigeminal Neuralgia in the United States.
Clinical Journal of Pain
, 34
(8)
pp. 691-699.
10.1097/AJP.0000000000000595.
Preview |
Text
Zakrzewska Treatment utilization in TN in USA Clin J Pain 2018.pdf - Published Version Download (4MB) | Preview |
Abstract
Background and Aim: Trigeminal neuralgia (TN) is a rare orofacial disorder characterized by severe unilateral paroxysmal pain in the region of the fifth cranial nerve. Clinical guidelines recommend carbamazepine (only US Food and Drug Administration-approved drug for TN) and oxcarbazepine as first-line therapies. We utilized the US Truven Health MarketScan database to examine treatment patterns among patients with TN. Methods: Included patients were aged 18 years and above, newly diagnosed with TN (≥2 TN diagnoses ≥14 days apart; no diagnosis in the previous year), continuously enrolled 1 year before index, with ≥3 years' follow-up postindex. We assessed utilization of selected pharmacotherapies (carbamazepine, oxcarbazepine, pregabalin, gabapentin, baclofen, duloxetine, topiramate), surgery (posterior fossa, radiosurgery), and injections (peripheral anesthetic injections, Gasserian ganglion procedures) for TN. Results: In total, 3685 patients were included (2425 commercial, 1260 Medicare; 71.8% female; age, mean [SD], 59 [15] y). Overall, 72.5% of patients received at least 1 studied medication, most commonly carbamazepine (51.7%) or gabapentin (48.6%). In total, 65% of pharmacologically treated patients had ≥2 treatment episodes; 41.6% had ≥3 (defined by a change in pharmacotherapy [monotherapy/combination] regimen). Overall, 12.3% had surgery and 7.3% injections; 42.9% received opioids for TN. Conclusions: In the 3 years after diagnosis, patients with TN in the United States receive a variety of pharmacological treatments, including opioids, despite carbamazepine being the only approved medication. A notable proportion utilize surgeries/injections. A high proportion of pharmacologically treated patients receive multiple treatment episodes, suggesting frequent therapy switching, perhaps because of suboptimal efficacy/tolerability. Our data suggest a high burden of illness associated with TN.
| Type: | Article |
|---|---|
| Title: | Characterizing Treatment Utilization Patterns for Trigeminal Neuralgia in the United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1097/AJP.0000000000000595 |
| Publisher version: | https://doi.org/10.1097/AJP.0000000000000595 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Anesthesiology, Clinical Neurology, Neurosciences & Neurology, trigeminal neuralgia, pharmacological treatment, surgery, treatment patterns, claims analysis, NEUROPATHIC PAIN TREATMENT, ANTIEPILEPTIC DRUGS, POPULATION, ADHERENCE, CARBAMAZEPINE, EPIDEMIOLOGY, GUIDELINES, MANAGEMENT, EFFICACY, THERAPY |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Eastman Dental Institute |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10057986 |
Archive Staff Only
 |
View Item |
